Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Disruption of Notch signaling aggravates irradiation-induced bone marrow injury, which is ameliorated by a soluble Dll1 ligand through Csf2rb2 upregulation.

Chen JJ, Gao XT, Yang L, Fu W, Liang L, Li JC, Hu B, Sun ZJ, Huang SY, Zhang YZ, Liang YM, Qin HY, Han H.

Sci Rep. 2016 May 18;6:26003. doi: 10.1038/srep26003.

2.

Loss of RUNX1 function results in enhanced granulocyte-colony-stimulating factor-mediated mobilization.

Lam K, Muselman A, Du R, Yan M, Matsuura S, Zhang DE.

Blood Cancer J. 2016 Mar 25;6:e407. doi: 10.1038/bcj.2016.20. No abstract available.

3.

Treatment with G-CSF reduces acute myeloid leukemia blast viability in the presence of bone marrow stroma.

Nomdedeu M, Lara-Castillo MC, Etxabe A, Cornet-Masana JM, Pratcorona M, Díaz-Beyá M, Calvo X, Rozman M, Costa D, Esteve J, Risueño RM.

Cancer Cell Int. 2015 Dec 21;15:122. doi: 10.1186/s12935-015-0272-3. eCollection 2015.

4.

TRAF3: a novel tumor suppressor gene in macrophages.

Lalani AI, Luo C, Han Y, Xie P.

Macrophage (Houst). 2015 Sep 30;2:e1009.

5.

Chronic neutrophilic leukemia with overexpression of EVI-1, and concurrent CSF3R and SETBP1 mutations: A case report.

Altangerel O, Cao S, Meng J, Liu P, Haiyan G, Xu Y, Zhao M.

Oncol Lett. 2015 Sep;10(3):1694-1700. Epub 2015 Jul 13.

6.

Endothelial CD36 Contributes to Postischemic Brain Injury by Promoting Neutrophil Activation via CSF3.

Garcia-Bonilla L, Racchumi G, Murphy M, Anrather J, Iadecola C.

J Neurosci. 2015 Nov 4;35(44):14783-93. doi: 10.1523/JNEUROSCI.2980-15.2015.

7.

Chronic neutrophilic leukemia: a clinical perspective.

Menezes J, Cigudosa JC.

Onco Targets Ther. 2015 Sep 1;8:2383-90. doi: 10.2147/OTT.S49688. eCollection 2015. Review.

8.

HoxA10 Terminates Emergency Granulopoiesis by Increasing Expression of Triad1.

Wang H, Bei L, Shah CA, Hu L, Eklund EA.

J Immunol. 2015 Jun 1;194(11):5375-87. doi: 10.4049/jimmunol.1401909. Epub 2015 Apr 20.

9.

Secondary acute promyelocytic leukemia following chemotherapy for gastric cancer: a case report.

Zhang YC, Zhou YQ, Yan B, Shi J, Xiu LJ, Sun YW, Liu X, Qin ZF, Wei PK, Li YJ.

World J Gastroenterol. 2015 Apr 14;21(14):4402-7. doi: 10.3748/wjg.v21.i14.4402.

10.

Granulocyte colony-stimulating factor potentiates all-trans retinoic acid-induced granulocytic differentiation in acute promyelocytic leukemia cell line HT93A.

Uchino Y, Iriyama N, Hatta Y, Takei M.

Cancer Cell Int. 2015 Mar 12;15:30. doi: 10.1186/s12935-015-0176-2. eCollection 2015.

11.

miR-155 is associated with the leukemogenic potential of the class IV granulocyte colony-stimulating factor receptor in CD34⁺ progenitor cells.

Zhang H, Goudeva L, Immenschuh S, Schambach A, Skokowa J, Eiz-Vesper B, Blasczyk R, Figueiredo C.

Mol Med. 2015 Apr 9;20:736-46. doi: 10.2119/molmed.2014.00146.

12.

The diversity of mutations and clinical outcomes for ELANE-associated neutropenia.

Makaryan V, Zeidler C, Bolyard AA, Skokowa J, Rodger E, Kelley ML, Boxer LA, Bonilla MA, Newburger PE, Shimamura A, Zhu B, Rosenberg PS, Link DC, Welte K, Dale DC.

Curr Opin Hematol. 2015 Jan;22(1):3-11. doi: 10.1097/MOH.0000000000000105. Review.

13.

Myeloid cell TRAF3 regulates immune responses and inhibits inflammation and tumor development in mice.

Lalani AI, Moore CR, Luo C, Kreider BZ, Liu Y, Morse HC 3rd, Xie P.

J Immunol. 2015 Jan 1;194(1):334-48. doi: 10.4049/jimmunol.1401548. Epub 2014 Nov 24.

14.

Immunosuppressive treatment in children with acquired aplastic anemia.

Yıldırmak Y, Erdem E, Telhan L, Kepekçi L.

Turk J Haematol. 2012 Jun;29(2):150-5. doi: 10.5505/tjh.2012.26779. Epub 2012 Jun 15.

15.

A Type II Arabinogalactan from Anoectochilus formosanus for G-CSF Production in Macrophages and Leukopenia Improvement in CT26-Bearing Mice Treated with 5-Fluorouracil.

Yang LC, Lu TJ, Lin WC.

Evid Based Complement Alternat Med. 2013;2013:458075. doi: 10.1155/2013/458075. Epub 2013 Sep 26.

16.

The genetic basis of myelodysplasia and its clinical relevance.

Cazzola M, Della Porta MG, Malcovati L.

Blood. 2013 Dec 12;122(25):4021-34. doi: 10.1182/blood-2013-09-381665. Epub 2013 Oct 17. Review.

17.

Severe congenital neutropenia and chronic neutrophilic leukemia: an intriguing molecular connection unveiled by oncogenic mutations in CSF3R.

Touw IP, Beekman R.

Haematologica. 2013 Oct;98(10):1490-2. doi: 10.3324/haematol.2013.090571. No abstract available.

18.

The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition.

Fleischman AG, Maxson JE, Luty SB, Agarwal A, Royer LR, Abel ML, MacManiman JD, Loriaux MM, Druker BJ, Tyner JW.

Blood. 2013 Nov 21;122(22):3628-31. doi: 10.1182/blood-2013-06-509976. Epub 2013 Sep 30.

19.

Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.

Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, Bottomly D, Wilmot B, McWeeney SK, Tognon CE, Pond JB, Collins RH, Goueli B, Oh ST, Deininger MW, Chang BH, Loriaux MM, Druker BJ, Tyner JW.

N Engl J Med. 2013 May 9;368(19):1781-90. doi: 10.1056/NEJMoa1214514.

20.

The effects of p38 MAPK inhibition combined with G-CSF administration on the hematoimmune system in mice with irradiation injury.

Li D, Wang Y, Wu H, Lu L, Wang X, Zhang J, Zhang H, Fan S, Fan F, Zhou D, Meng A.

PLoS One. 2013 Apr 30;8(4):e62921. doi: 10.1371/journal.pone.0062921. Print 2013.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk